Literature DB >> 20430040

Reduced expression of angiotensin I-converting enzyme in caveolin-1 knockout mouse lungs.

Nikolaos A Maniatis1, Irina V Balyasnikova, Roman Metzger, Maricela Castellon, David J Visintine, David E Schwartz, Richard D Minshall, Sergei M Danilov.   

Abstract

Reduced lung capillary expression of angiotensin I-converting enzyme (ACE), a key enzyme in cardiovascular pathophysiology, and of caveolin-1, an important regulator of endothelial cell signalling, has been demonstrated in various models of pulmonary arterial hypertension (PAH). We addressed the relationship between PAH and ACE expression in caveolin-1 knockout mice (Cav1(-/-)), which have moderate PAH. Tissue ACE activity was reduced by 50% in lungs from 3-month-old Cav1(-/-) mice compared to wild type (WT). A similar reduction in lung endothelial ACE expression was observed by measuring the lung uptake of (125)I-labeled monoclonal anti-ACE antibody and by quantitative immunohistochemistry. These alterations in ACE are limited to capillary segments of the pulmonary circulation. Functionally, the increase in pulmonary artery pressure (PAP) in response to ACE conversion of angiotensin I to angiotensin II in isolated, perfused mouse lungs was reduced significantly in Cav1(-/-) mice compared to WT. Thus, these complementary approaches demonstrate the dependence of lung microvascular endothelial cell ACE protein expression on caveolin-1 expression and underscore the vital role of caveolin-1-regulated pulmonary vascular homeostasis on endothelial ACE expression and activity. In summary, we have revealed a novel role of caveolin-1 in the regulation of ACE expression in pulmonary capillary endothelial cells. Further understanding of the mechanism by which reduced caveolin-1 expression leads altered pulmonary vascular development, PAH, and reduced ACE expression may have important clinical implications in patients with these severe lung diseases. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20430040      PMCID: PMC2919634          DOI: 10.1016/j.mvr.2010.04.008

Source DB:  PubMed          Journal:  Microvasc Res        ISSN: 0026-2862            Impact factor:   3.514


  46 in total

Review 1.  Vesicle formation and trafficking in endothelial cells and regulation of endothelial barrier function.

Authors:  Richard D Minshall; Chinnaswamy Tiruppathi; Stephen M Vogel; Asrar B Malik
Journal:  Histochem Cell Biol       Date:  2002-01-22       Impact factor: 4.304

2.  Loss of caveolae, vascular dysfunction, and pulmonary defects in caveolin-1 gene-disrupted mice.

Authors:  M Drab; P Verkade; M Elger; M Kasper; M Lohn; B Lauterbach; J Menne; C Lindschau; F Mende; F C Luft; A Schedl; H Haller; T V Kurzchalia
Journal:  Science       Date:  2001-08-09       Impact factor: 47.728

3.  Pulmonary capillary endothelial dysfunction in early systemic sclerosis.

Authors:  S E Orfanos; E Psevdi; N Stratigis; D Langleben; J D Catravas; M Kyriakidis; H M Moutsopoulos; C Roussos; P G Vlachoyiannopoulos
Journal:  Arthritis Rheum       Date:  2001-04

4.  Lung uptake of antibodies to endothelial antigens: key determinants of vascular immunotargeting.

Authors:  S M Danilov; V D Gavrilyuk; F E Franke; K Pauls; D W Harshaw; T D McDonald; D J Miletich; V R Muzykantov
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2001-06       Impact factor: 5.464

5.  cAbl tyrosine kinase mediates reactive oxygen species- and caveolin-dependent AT1 receptor signaling in vascular smooth muscle: role in vascular hypertrophy.

Authors:  Masuko Ushio-Fukai; Lian Zuo; Satoshi Ikeda; Taiki Tojo; Nikolay A Patrushev; R Wayne Alexander
Journal:  Circ Res       Date:  2005-09-08       Impact factor: 17.367

6.  Inhibitory effect of reactive oxygen species on angiotensin I-converting enzyme (kininase II).

Authors:  B Michel; M Grima; L B Nirina; C Ingert; C Coquard; M Barthelmebs; J L Imbs
Journal:  Clin Exp Pharmacol Physiol       Date:  2001-03       Impact factor: 2.557

7.  Caveolin-1 null mice are viable but show evidence of hyperproliferative and vascular abnormalities.

Authors:  B Razani; J A Engelman; X B Wang; W Schubert; X L Zhang; C B Marks; F Macaluso; R G Russell; M Li; R G Pestell; D Di Vizio; H Hou; B Kneitz; G Lagaud; G J Christ; W Edelmann; M P Lisanti
Journal:  J Biol Chem       Date:  2001-07-16       Impact factor: 5.157

8.  Pulmonary angiotensin-converting enzyme (ACE) binding and inhibition in humans. A positron emission tomography study.

Authors:  F Qing; T J McCarthy; J Markham; D P Schuster
Journal:  Am J Respir Crit Care Med       Date:  2000-06       Impact factor: 21.405

9.  Pulmonary capillary endothelium-bound angiotensin-converting enzyme activity in acute lung injury.

Authors:  S E Orfanos; A Armaganidis; C Glynos; E Psevdi; P Kaltsas; P Sarafidou; J D Catravas; U G Dafni; D Langleben; C Roussos
Journal:  Circulation       Date:  2000-10-17       Impact factor: 29.690

10.  Temperature-induced selective death of the C-domain within angiotensin-converting enzyme molecule.

Authors:  Sergei Voronov; Natalia Zueva; Victor Orlov; Alexander Arutyunyan; Olga Kost
Journal:  FEBS Lett       Date:  2002-07-03       Impact factor: 4.124

View more
  2 in total

Review 1.  Molecular regulation and clinical significance of caveolin-1 methylation in chronic lung diseases.

Authors:  Furong Yan; Lili Su; Xiaoyang Chen; Xiangdong Wang; Hongzhi Gao; Yiming Zeng
Journal:  Clin Transl Med       Date:  2020-04-16

2.  Caveolin and caveolae in age associated cardiovascular disease.

Authors:  Heidi N Fridolfsson; Hemal H Patel
Journal:  J Geriatr Cardiol       Date:  2013-03       Impact factor: 3.327

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.